Skip to main content
. Author manuscript; available in PMC: 2013 Aug 15.
Published in final edited form as: Acta Oncol. 2012 Mar 30;51(6):781–789. doi: 10.3109/0284186X.2011.653009

Table IV.

Association between Bcl-2 and DFS in the Danish Cohort of BIG 1 - 98 by univariate analysis.a

Bcl-2b n Periodc HR (95% CI) p
0–9% 37 2.90 (1.83–4.61) 0.0001
10–49% 32 1.23 (0.65–2.34) 0.52
≥ 50%/weak + mod 234 0–5 years 1.41 (1.06–1.90) 0.02
5–10 years 0.49 (0.23–1.02) 0.06
≥ 50%/strong 888 1.00 (reference)

CI, confidence interval; HR, hazard ratio; mod, moderate.

a

Model stratified by randomization option, allocated treatment and age at randomization.

b

Global test for Bcl-2 (p = 0.0002).

c

Time-dependent variables. If nothing is mentioned the follow-up period is 0 – 10 years postrandomization.